Session on Global Trends in IP Law in Pharma Market Context

At the largest innovation forum in the country Open Innovations, which this year was held at the Skolkovo Technopark, a session was dedicated to issues related in the regulation of IP in the pharmaceutical industry. Director of the Institute Alexey Ivanov and senior researcher Ioannis Lianos took part in the discussion.

In recent years, intellectual property issues in the pharmaceutical industry have become particularly important. On the one hand, large pharmaceutical companies are investing substantial financial and intellectual resources in the development of new breakthrough solutions, which requires a sufficient level of legal protection for the results of these efforts and new products, while on the other hand, there are clear needs of the population regarding the availability of the most in demand and socially significant drugs, which may require a weakening of the force of intellectual property in the context of monopoly exclusion dynamics. This raises the question of the balance of interests in the implementation of patent protection in the pharmaceutical industry.

 

Concerning the question of the protection of competition in the pharmaceutical industry, the Institute has been engaged in the work of the NTI IPNet group, and closely cooperates in this directive with the Federal Antimonopoly Service of Russia.

 

The discussion was moderated by Chairman of the Board of the Skolkovo Foundation, Igor Drozdov, and among the participants alongside Alexey and Ioannis were representatives of 'big pharma', and head of the Department for Control over Social Sphere and Trade, Timofey Nizhegorodtsev.